| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Internal Medicine (Nuclear Medicine), University of Michigan Medical School and the School of Pharmacy, Ann Arbor, Michigan 48104
In a repetition of the work of Blois and Kallman and of Hempel and Deimel studying the tissue distribution of radioactivity concentration following injections in mice with melanomas of DL-3,4-dihydroxyphenylalanine-2-14C (dopa), DL-dopa-1-14C, and L-dopa-3H, little incorporation of radioactivity was found in the melanoma. A maximum 14C concentration ratio of melanoma: serum of 4 was attained at 24 hr. Radioactivity in a more pigmented area of a Syrian hamster melanoma varied from 6.3 to 33.4 times that of serum. The uptake of 14C appeared to depend to a large extent upon the degree of pigmentation. Pretreatment with pyrogallol, a competitive inhibitor of catechol-o-methyl-transferase, the enzyme most responsible for the degradation of circulating catecholamines, did not enhance uptake in the melanoma but significantly enhanced the uptake in the adrenal gland. Administration of 14C- and 125I-labeled 5,6-diacetoxyindole derivatives failed to result in concentration of radioactivity in melanoma or adrenal, possibly because an earlier precursor of melanin enters the melanosome before these late metabolic steps occur.
1 This work was supported by grants from the NIH, CA-5134-03 and CA-08429-02, the Michigan Memorial Phoenix Project, #317, the Nuclear Medicine Research Fund, and the American Cancer Society, PRA-18.
Received 12/22/66. Accepted 4/ 4/67.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |